New Science 37® CNS Survey Confirms Growing Trend in Clinical Trials Landscape
March 01 2022 - 7:55AM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial
Operating System™, today published new CNS (Central Nervous System)
therapeutic data validating the growing trend toward
decentralization as two-thirds of CNS survey respondents plan to
execute an agile or decentralized clinical trial in 2022, an
increase of more than 35 percent from last year.
According to analysis, the CNS Research & Development spend
will reach $32 billion USD by 2026, resulting in more than 4,000
clinical trials¹. To uncover these new trends in CNS clinical
trials methodologies, Science 37 conducted a study of more than 70
clinical research executives, between December 2021 and January
2022.
“These insights confirm: agile designs and decentralized methods
are the way forward to reduce the burden and enable more universal
access for patients and providers, anywhere,” said Drew Bustos,
Chief Strategy & Marketing Officer at Science 37, and co-author
of How Agile Clinical Trials are Impacting CNS Research. “This
report aligns with the shift we’re seeing from CNS sponsors and
similar to the market overall. It’s encouraging as we strive toward
creating more equitable access to clinical research with more and
more patient-centric approaches.”
For CNS studies, survey respondents cited unexpected delays,
data quality and limited patient populations among the key
challenges for clinical trials, with effective patient recruitment
as the single biggest challenge by more than 100% comparatively to
the second challenge of endpoint collection. Being able to
eliminate geographic barriers with agile and decentralized
approaches and helping to ease patient burden can help alleviate
these concerns and enable more efficient centralized enrollment
into studies.
The new data and insights also paint a vivid picture of the
clinical trials landscape for the year ahead for CNS studies,
suggesting significant increases in agile and decentralized
approaches across numerous conditions—including major depressive
disorder, Alzheimer’s disease, and Parkinson’s disease—and executed
with a myriad of permutations of patient communities, mobile
nursing, telemedicine investigators and connected devices – further
demonstrating the need for a centralized Operating System with
unified technology and centralized networks to effectively
execute.
Among the findings:
- Less than 60 percent of CNS respondents are planning to execute
a traditional, site-based clinical trial in 2022, down from three
in four for the previous year.
- Unexpected delays, data quality, and limited patient
populations all ranked highly among the issues keeping respondents
up at night, regarding CNS trials in general.
- Respondents cited the greatest single challenge of running an
effective CNS study was patient recruitment by more than 100%
comparatively to the second challenge of endpoint collection.
- Electronic clinical outcomes assessment (eCOA) and electronic
patient-reported outcomes (ePRO) were cited as the most prevalent
decentralized components in CNS, with two-thirds of CNS respondents
planning to use these tools – showing the rising embrace of digital
data collection and evidence generation.
- Among the largest-growing decentralized components of CNS
studies cited were mobile nurses, up 40 percent and up 38 percent,
respondents cited usage of Metasites™ or virtual sites that can
enable more universal geographic coverage and access for
patients.
- The three greatest perceived
benefits of including agile and decentralized components in CNS
clinical trials were increased patient retention (more than 55
percent), increased patient diversity and faster patient
recruitment (both more than 50 percent).
You can download a copy of the full report for free at
www.science37.com.
About Science 37Science 37, Inc.’s (Nasdaq:
SNCE) mission is to enable universal access to clinical
research—making it easier for patients and providers to participate
from anywhere and helping to accelerate the development of
treatments that impact patient lives. As a pioneer of decentralized
clinical trials, the Science 37 Clinical Trial Operating System
(OS) supports today’s more agile clinical research designs with its
full-stack, end-to-end technology platform and specialized networks
of patient communities, telemedicine investigators, mobile nurses,
remote coordinators and connected devices. Configurable to enable
any study type, the Science 37 OS enables up to 15x faster
enrollment, 28% better retention and 3x more diverse patient
population with industry-leading workflow orchestration, evidence
generation and data harmonization. For more information, visit
https://www.science37.com.
About the Agile Clinical Trial: The
use of decentralized tools and methodologies is increasing. With
these advances, patients will be able to participate from their
home, a site, or a combination of home and site; and providers will
be able to participate on or off-premise. This symbiotic clinical
trial or the “Agile Clinical Trial” requires: The ability to
activate any provider and any patient, regardless of premises; a
network of patient communities, telemedicine investigators, mobile
nurses, and remote coordinators—all with a flexible Operating
System to seamlessly navigate between on-site and off-site.
Forward Looking StatementsThis presentation
contains certain forward-looking statements within the meaning of
the federal securities laws, including statements regarding the
services offered by Science 37 Holdings, Inc. (“Science 37” or the
“Company”) and the markets in which it operates, and Science 37’s
projected future results. These forward-looking statements
generally are identified by the words “believe,” “project,”
“expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result” and similar expressions.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to: (i) volatility in the price
of Science 37’s securities due to a variety of factors, including
changes in the competitive and highly regulated industries in which
Science 37 plans to operate, variations in performance across
competitors, changes in laws and regulations affecting Science 37’s
business and changes in its capital structure, (ii) the ability to
implement business plans, forecasts, and other expectations, and to
identify and realize additional opportunities, (iv) the risk that
Science 37 may never achieve or sustain profitability, (iii) the
risk that Science 37 will need to raise additional capital to
execute its business plan, which may not be available on acceptable
terms or at all; and (v) the potential adverse effects of the
ongoing global COVID-19 pandemic. The foregoing list of factors is
not exhaustive. You should carefully consider the foregoing factors
and the other risks and uncertainties described in the “Risk
Factors” section of Amendment No. 2 to the S-1 Registration
Statement filed by Science 37 with the U.S. Securities and Exchange
Commission (the “SEC”) on January 20, 2022, and other documents
filed by Science 37 from time to time with the SEC. These filings
identify and address other important risks and uncertainties that
could cause actual events and results to differ materially from
those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Science 37 assumes no obligation and does not intend to update
or revise these forward-looking statements, whether as a result of
new information, future events, or otherwise, except as required by
law. Science 37 does not give any assurance that Science 37 will
achieve its expectations.
¹ Source: Evaluate Pharma
MEDIA INQUIRIES:Margie Koomanpr@science37.com984. 377.3737
INVESTOR RELATIONS:Caroline Paulinvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024